

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/66	A1	(11) International Publication Number: WO 94/14473 (43) International Publication Date: 7 July 1994 (07.07.94)
<p>(21) International Application Number: PCT/GB93/02600</p> <p>(22) International Filing Date: 20 December 1993 (20.12.93)</p> <p>(30) Priority Data: 9226729.3 22 December 1992 (22.12.92) GB</p> <p>(71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): PRIETO VALTUENA, Jesus [ES/ES]; Tudela, 22-4°, E- Pamplona (ES). BELOQUI RUIZ, Oscar [ES/ES]; Travesia Monasterio Urdax, 2-5°D, E-Pamplona (ES).</p> <p>(74) Agent: STOTT, Michael, John; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB).</p>		<p>(81) Designated States: AU, CA, HU, JP, KR, NO, PL, RU, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: THERAPEUTIC COMBINATION CONTAINING INTERFERON</p> <p>(57) Abstract</p> <p>The present invention relates to a therapeutic combination, more particularly a combination therapy involving the use of human interferon. The therapy involves the treatment of conditions susceptible to treatment with human interferon, with a combination of a human interferon and a free radical scavenger or precursor or inducer thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WO 94/14473

PCT/GB93/02600

- 1 -

THERAPEUTIC COMBINATION CONTAINING INTERFERON

The present invention relates to a therapeutic combination, more particularly a combination therapy involving the use of human interferon.

The first and localised response of an animal to a virus infection is to produce the lymphokine interferon. Originally thought to be a single molecule, interferons are now recognised as a large family of proteins, old in evolutionary terms, and widely distributed in the animal kingdom. Although there may be some limited cross-reactivity, interferons are generally species specific. Three types of interferon have been characterised originally known as leukocyte, fibroblast and immune interferon and now designated interferons α , β and γ respectively.

Human interferon- α can be produced by many different cell types and HPLC has resolved this type of interferon into over 30 subtypes each coded by a different gene. Human interferon- β is generally considered to be a single substance and is made by fibroblasts. Human interferon- γ is also a single substance made by helper-induced subsets of T-lymphocytes on exposure to antigen or by exposing human white blood cells, T-lymphocytes, or T-lymphoblastoid cells to mitogens.

Human interferon- α is manufactured in commercial amounts by stimulating the Namalwa human lymphoblastoid cell line with Sendai virus to produce a natural mixture of at least 21 subtypes of interferon- α which are then purified by chromatography to a purity of 95% and a specific activity of about 100×10^6 IU/mg protein. Such a product, identified as human interferon α -NI, is commercially available under the name WELLFERON (Registered Trade Mark of The Wellcome Foundation Limited). Natural human interferon- β is derived from human diploid fibroblasts, usually from neonatal tissue, production being induced for example by adding synthetic double stranded RNA. Human interferon- γ may be made from buffy coats, with a mitogen such as Staphylococcus enterotoxin A as inducer.

Human interferons- α , - β and - γ can also be produced using recombinant DNA technology although when produced by expression of the relevant gene in bacterial cells, recombinant interferons may not have the same tertiary structure as the natural molecules. Similarly, interferons produced in bacterial cells will not be glycosylated and although this does not appear to affect the biological activity of the molecule when

WO 94/14473

PCT/GB93/02600

- 2 -

tested *in vitro*, it could alter conformation and antigenicity and may influence distribution in the body. Such a recombinant human interferon preferably possesses greater than 90% amino-acid homology with a natural human interferon; more preferably 95% homology, yet more preferably 97% homology, yet more preferably 98% homology, yet more preferably 99% homology and most preferably 100% homology. Recombinant human interferons are available commercially and examples are interferon α -2a (ROFERON - Roche) and interferon γ -2a (INTRON -Schering). These molecules differ by a single amino acid residue at position 23 (lysine in ROFERON and arginine in INTRON).

Human interferons have been used for some years in the treatment of hepatitis. The first trials in the mid 1970s used human leukocyte interferon produced from buffy coat cells left over after the production of plasma from donated blood and this necessarily limited the quantity available. In the early 1980s advances in production techniques led to the use of both natural and recombinant human interferon- α or the treatment of chronic hepatitis B. Whilst this treatment can be regarded as successful in many cases, response rates to treatment with human α -interferons alone, as judged by sustained loss of viral markers, are generally considered to be less than 50%. Human interferons- β and - δ have also been investigated for use in chronic hepatitis B but have not become established treatments.

All three types of human interferon have also been investigated in the therapy of chronic hepatitis C although low availability of interferon- β has limited work with this type of interferon. Quite extensive trials have been carried out using the α -interferons referred to above (Interferon α -2a, interferon α -2b and lymphoblastoid interferon) and results have been encouraging in that complete response occurs in about 40% of patients. However, relapse rates of about 50% have been observed 6 months after treatment so that only 20 to 25% of patients may benefit in the long term.

For a complete review of the use of interferons in the treatment of hepatitis, reference can be made to the book "Interferons in the Treatment of Chronic Virus Infection of the Liver" by Eddleston and Dixon, Pennine Press, 1990.

In addition, interferons have been proposed for use in the therapy of a number of other conditions including viral diseases other than hepatitis. disorders involving the

WO 94/14473

PCT/GB93/02600

- 3 -

immune system, including autoimmune conditions, and cancers of various sorts including renal cancer, breast cancer, colon cancer, Kaposi's Sarcoma, glioma and malignant haematological conditions.

There is some evidence, particularly in the context of HIV, to suggest that chronic viral infections may cause oxidative stress in the infected organism. Induction of oxidative stress by viruses may be due to a variety of mechanisms including activation of phagocytic cells by immunocomplexes, promotion of free radical formation by pro-inflammatory cytokines (TNF α , IL6) and generation of reactive oxygen species by direct interaction between viral surface glycoproteins and cell membranes.

A number of substances are known which act as free radical scavengers at the level of the cell or the whole organism. For example reduced glutathione is a widely distributed non-protein thiol present in most mammalian cells which has been implicated in a variety of metabolic functions including detoxification reactions against free radicals. Glutathione is the main intracellular defence mechanism against oxidative stress and factors that increase free radical formation lead to consumption of intracellular glutathione stores. Glutathione also plays an important immunoregulatory role in modulating lymphocyte activation and proliferation, T-cell cytotoxicity and macrophage-lymphocyte interactions.

N-acetyl cysteine has been known for many years as a mucolytic, a corneal vulvary and as an antidote to acetaminophen poisoning. The compound has a relatively mild reducing effect and is thought to act as a mucolytic by splitting disulphide bonds in mucoproteins. There have been a number of reports that reduced glutathione levels may be lowered in some chronic viral conditions, in particular HIV infections. N-acetyl cysteine is a precursor and thus an inducer of glutathione and N-acetyl cysteine has been proposed as a therapeutic agent for use in the case of HIV infection.

EP-A-0 269 017 (Cetus) relates to the combination of a lymphokine or cytotoxin and a free radical scavenger or metabolic inhibitor for the treatment of biological damage to mammalian hosts caused by free radical production. Although the specification refers in passing to interferons as the lymphokine and also mentions infections as a possible cause of biological damage, the specification is essentially concerned with free radicals which may be generated during the treatment of cancer. The biological data

WO 94/14473

PCT/GB93/02600

- 4 -

given in the specification relate entirely to cancer and are concerned mainly with the administration of $\text{TNF}\alpha$ in murine fibrosarcoma.

The present invention relates to the use of a free radical scavenger or a precursor or inducer thereof as an adjunct to therapy with a human interferon.

Thus according to one aspect, the present invention provides a method for the treatment of a patient suffering from a condition susceptible to therapy with an interferon which comprises administration to the patient of an effective amount of a human interferon, and wherein a free radical scavenger or a precursor or inducer thereof is also administered for all or part of the duration of the administration of the human interferon.

According to another aspect, the invention provides the use of a human interferon for the manufacture of a medicament for use in the treatment of a condition susceptible to therapy with an interferon by a method wherein a free radical scavenger or a precursor or inducer thereof is also administered for all or part of the duration of the administration of the human interferon.

According to a still further aspect, the invention provides the use of a free radical scavenger or a precursor or inducer thereof for the manufacture of a medicament for the treatment of a condition susceptible to therapy with an interferon by a method involving administration of a human interferon and wherein the free radical scavenger or a precursor or inducer thereof is also administered for all or part of the duration of the administration of the human interferon.

The condition susceptible to therapy with an interferon may be any of the conditions for which human interferons have become established or have been proposed as effective treatments. Such conditions include viral infections, such as viral hepatitis, infections caused by human papilloma virus, cytomegalovirus and HIV, non-viral infections such as tuberculosis, and conditions such as asthma.

The present invention is particularly applicable to the use of human interferons in the therapy of hepatitis. As already indicated, although such therapy is of considerable benefit in many cases, the response rate is relatively low and in the case of hepatitis C

WO 94/14473

PCT/GB93/02600

- 5 -

there is a substantial rate of relapse. Accordingly, there is a considerable need for improvements in the therapy of hepatitis with human interferon to overcome these problems.

Example of human interferon of use with the present invention include those mentioned hereinbefore.

According to another aspect, the present invention provides a method for the treatment of a viral hepatitis infection by administration of a human interferon, wherein a free radical scavenger or a precursor or inducer thereof is also administered for all or part of the duration of the administration of the human interferon.

According to a further aspect the invention provides the use of a human interferon for the manufacture of a medicament for the treatment of a viral hepatitis infection by a method wherein a free radical scavenger or a precursor or inducer thereof is also administered for all or part of the duration of the administration of the human interferon.

According to a still further aspect, the invention provides the use of a free radical scavenger or a precursor or inducer thereof for the manufacture of a medicament for the treatment of a viral hepatitis infection by a method involving administration of a human interferon and wherein the free radical scavenger or a precursor or inducer thereof is also administered for all or part of the duration of the administration of the human interferon.

According to a further aspect, the invention provides potentiated combinations also known as synergistic combinations, of a human interferon and a free radical scavenger or precursor or inducer thereof for use in the treatment of a condition susceptible to therapy with an interferon. The active ingredients of potentiated combinations of the invention may be administered concurrently or sequentially as separate formulations or as a single combined formulation. If there is sequential administration, the delay in administering the second of the active ingredients should not be such as to lose the benefit of a potentiated therapeutic effect of the combination of the active ingredients.

WO 94/14473

PCT/GB93/02600

- 6 -

The present invention is applicable to the treatment of viral hepatitis in all of its forms, five types now being recognised designated hepatitis A, B, C, D, and E respectively.

Hepatitis A is an acute viral infection with an incubation period of under 40 days transmitted by the faecal-oral route. The virus is a member of the picornavirus family and consists of a 27nm spherical, non-enveloped particle. The viral genome has been sequenced and comprises a single strand of RNA containing ca. 7480 bases.

Hepatitis B is a universal and serious virus disease with an estimated over 200 million carriers world wide. When it was known as serum hepatitis, the disease was diagnosed on the basis of the appearance of symptoms 2 to 3 months after blood transfusion, the injection of human plasma fractions or the use of unsterilised needles or syringes. The recognition of serum markers for hepatitis B has confirmed the importance of skin penetration and in particular blood in the transmission of the virus. Following the acute phase of the disease, the majority of adult patients recover spontaneously within a matter of weeks but a proportion do not clear the virus after many months and become chronic carriers. Hepatitis B virus belongs to the hepadna virus family whose genome consists of a small, incompletely double-stranded circular piece of DNA that replicates by copying its DNA into RNA and then re-copying the RNA to DNA using reverse transcriptase.

Non-A, non-B hepatitis is being recognised as an increasingly serious international health problem. At least 80% of cases of chronic post-transfusional non-A, non-B hepatitis have been shown to be due to the virus now identified as hepatitis C and this virus probably accounts for virtually all cases of post-transfusional hepatitis in clinical settings where blood products are screened for hepatitis B. Whereas approximately half of the cases of acute hepatitis C infection resolve spontaneously over a period of months, the remainder become chronic and in many if not all such cases chronic active hepatitis ensues with the potential for cirrhosis and hepatocellular carcinoma. The structure of the hepatitis C virus genome has recently been elucidated and the virus has been characterised as a single stranded RNA virus with similarities to flaviviruses.

Hepatitis D virus was first recognised in 1977 following identification of a novel antigen in certain carriers of hepatitis B. The virus requires hepatitis B (or a closely related hepadna virus) as a helper virus to replicate although replication is sufficiently

WO 94/14473

PCT/GB93/02600

- 7 -

efficient that it can attain a higher titre than the helper virus in the serum. The hepatitis D genome consists of covalently closed circular RNA and has some structural similarity to certain circular viroids or virus-like agents found in plants. Hepatitis D infection is associated with aggressive liver disease and is more often found in patients with severe disease (chronic active hepatitis or cirrhosis) than in those with chronic persistent hepatitis.

Hepatitis E virus is related to the virus which causes Hepatitis A (Reyes et al., Science 247, 1335-1339 (1990)) and produces an acute form of hepatitis with no chronic phase. The virus is enteric, water borne and normally transferred by the faecal/oral route. It is particularly prevalent in the Indian sub-continent and produces a high mortality rate in pregnant women.

The present invention is also applicable to the treatment of human papilloma virus which is the agent responsible for non-genital warts, juvenile laryngeal papilloma, condyloma accuminata and which is involved in cervical cancer. The invention is also applicable to the treatment of other viral infections such as those caused by human cytomegalovirus and HIV. The invention is also applicable to the treatment of non-viral infections such as tuberculosis and conditions such as asthma.

The human interferon for use according to the invention may be any of the three types referred to above, i.e. interferon- α , interferon- β or interferon- γ . Generally the human interferon will be interferon- α or interferon- γ . Preferably the human interferon is human interferon- α , more preferably human interferon- α derived from a human cell line in culture or a recombinant human interferon- α . According to one preferred embodiment, the human interferon is recombinant interferon α -2a or interferon α -2b, for example one of the products marketed under the trade names ROFERON and INTRON. According to another particularly preferred embodiment, the human interferon is human lymphoblastoid interferon (interferon α N1), for example the product marketed by The Wellcome Foundation Ltd. under the trade name WELLFERON.

The term 'human interferon' is intended to include any wild-type interferon, the sequence of which was determined from a human, and any allele, variant or mutant thereof which substantially conserves the activity of the corresponding wild-type

WO 94/14473

PCT/GB93/02600

- 8 -

sequence and which possesses greater than 80% sequence homology with the corresponding wild-type sequence.

Human interferons may be formulated for administration according to the invention in the same manner as for use alone in the treatment of the condition in question, for example hepatitis. Thus the interferon is generally administered parenterally, for example by injection, preferably subcutaneous injection. Preferably the interferon is formulated as an aqueous preparation or as a lyophilised product intended for reconstitution with a suitable vehicle, for example water for injection. The formulation may also contain a suitable carrier diluent or stabiliser, for example another human protein such as human serum albumin.

The human interferon will generally be administered in accordance with the treatment protocols already established for the product in question. For example human interferon- α whether lymphoblastoid or recombinant, may be administered at a dose of 1 to 10 Mega Units of interferon per day. The dose may be administered on 3 or more days per week, preferably 3 times per week. A preferred dose range is 2 to 6 Mega Units of interferon per day on 3 or more days per week, preferably 3 times per week, and particular doses of interferon are 5 Mega Units or, most preferably, 3 Mega Units per day or 3 or more days per week, preferably 3 times per week. In the treatment of hepatitis, the duration of administration of the interferon is usually a period of several weeks, for example 12 to 30 weeks, in particular about 24 weeks, although longer periods of treatment of up to a year or more may be appropriate in some cases.

As used herein, the term "free radical scavenger or precursor or inducer thereof" means any material which is capable, on administration to a host, of reducing the level of free radicals (also referred to as oxidative stress) within the host. The material may bring about this reduction in the level of free radicals by direct scavenging of free radicals or by inducing, whether as a direct biological precursor or otherwise, the production within the host of a material having a scavenging effect on free radicals. Alternatively, the material may reduce the level of free radicals by exerting an inhibiting effect in the processes which lead to the generation of free radicals.

Preferred free radical scavengers or precursors or inducers thereof include glutathione and precursors thereof such as derivatives of the naturally occurring amino acid

WO 94/14473

PCT/GB93/02600

- 9 -

cysteine. One particularly preferred precursor of glutathione is N-acetyl cysteine. As indicated above, N-acetyl cysteine already has an established pharmaceutical use as a mucolytic and pharmaceutical preparations of the compound are available commercially. Other free radical scavengers or precursors or inducers thereof include vitamin A, vitamin C (ascorbic acid), vitamin E, uric acid, buthionine sulfoxime, diethyl maleate metronidazole, superoxide dismutase and methionine. Materials which inhibit the generation of free radicals include inhibitors of xanthine oxidase such as allopurinol.

The free radical scavenger or precursor or inducer thereof should be administered in a form and dose such that it is capable of reducing free radical generation and/or relieving the effects of free radical generation (oxidative stress) in the host. Administration may be by any convenient route, for example oral or parenteral, depending on the nature of the material. Oral administration is preferred where possible.

N-acetyl cysteine is preferably formulated for oral administration in the form of tablets or granules or as a liquid preparation, for example a syrup. An appropriate dose of N-acetyl cysteine is in the range 200mg to 4g per dose administered up to 4 times per day, for example 400 to 800mg administered 4 times per day, preferably 600mg administered 4 times per day.

Although the therapy provided according to the invention, for example for viral hepatitis, consists of the combined administration of a human interferon and a free radical scavenger or precursor or inducer thereof, the two medicaments will generally be administered as separate preparations. However, in some circumstances, there may be an advantage in administering the two components as a combined preparation and the invention extends to such combined preparations.

Thus according to a further aspect the invention provides a pharmaceutical composition comprising a human interferon together with a free radical scavenger or a precursor or inducer thereof.

In general any such combined preparation will be in a form intended for parenteral administration, for example injection. Such a combined preparation may be presented

WO 94/14473

PCT/GB93/02600

- 10 -

in liquid form or in a solid form, with the human interferon lyophilised, and suitable for reconstitution into a liquid form.

It may also be appropriate to present the two medicaments together in a suitable form for separate administration. According to another aspect the invention provides a twin pack comprising in association for separate administration a human interferon and a free radicle scavenger or a precursor or inducer thereof.

The present invention is particularly applicable to the therapy of hepatitis B or hepatitis C. As indicated above, administration of human interferon, particularly recombinant or lymphoblastoid interferon- α is already an established therapy for hepatitis B. In addition, a number of trials have indicated that the same therapy is also of considerable benefit in the treatment of hepatitis C. According to the present invention, therapy of patients suffering from hepatitis, in particular hepatitis B or hepatitis C, with interferon will be carried out essentially in accordance with the established protocols with the addition of treatment with a free radical scavenger or a precursor or inducer thereof for all or part of the duration of therapy with the human interferon.

Serum alanine aminotransferase (ALT) levels are a highly sensitive marker for liver dysfunction. Hepatitis B and hepatitis C infections are both characterised by raised ALT levels and the progress of the disease is generally monitored by determination of serum ALT. As indicated above, only about 50% or less of patients with hepatitis B or hepatitis C respond to treatment with human interferon- α in as demonstrated by a significant clearing of viral markers or lowering of ALT levels.

According to one embodiment of the invention, which is particularly applicable to the treatment of hepatitis B or hepatitis C, most particularly hepatitis C, treatment with human interferon, particularly human interferon-a, is undertaken in the usual manner for a period of several weeks, for example 12 to 30 weeks, in particular about 24 weeks. For patients who fail to respond to this initial course of treatment with human interferon as demonstrated by significantly reduced serum ALT levels, treatment is continued with the human interferon and with the additional treatment with the free radical scavenger or a precursor or inducer thereof, preferably glutathione or a precursor or inducer thereof, most preferably N-acetyl cysteine. Treatment with the

WO 94/14473

PCT/GB93/02600

- 11 -

human interferon and the free radical scavenger or precursor or inducer thereof may be continued for a further period of several weeks, for example 12 to 30 weeks, in particular about 24 weeks. In accordance with a preferred embodiment of the invention, this treatment protocol is applied to the treatment of hepatitis C with human lymphoblastoid interferon (human interferon α -N1).

As also indicated above, certain patients with hepatitis B or hepatitis C may respond initially to treatment with human interferon, particularly human interferon- α , but may subsequently relapse. Such patients may also benefit from a combined course of treatment with the human interferon and the free radical scavenger or a precursor or inducer thereof as outlined above.

It should be understood that doses of the human interferon and the free radical scavenger or a precursor or inducer thereof will vary depending on the patient and the precise condition from which the patient is suffering. Ultimately, the treatment will be under the control of and will be the responsibility of the attendant physician.

The invention is further illustrated by the following pilot study which should not be regarded as in any way limiting on the scope of the invention.

EXAMPLE

1. Introduction

Hepatitis C virus (HCV) is responsible for most cases of posttransfusional and sporadic non-A, non-B hepatitis. Chronification of the infection is very common, leading to chronic hepatitis, cirrhosis and, ultimately, malignant degeneration. Several controlled studies have shown that α -interferon (IFN) is useful in the treatment of chronic hepatitis C (CHC), but the response rate averages 50% and the frequency of relapse, after IFN cessation, may reach 30-40%. Accordingly, the proportion of patients with CHC sustaining normal transaminase levels after IFN withdrawal is only around 20-40% of all treated cases.

WO 94/14473

PCT/GB93/02600

- 12 -

Reduced glutathione (GSH) is an important antioxidant in mammalian cells, being implicated in a great variety of cellular functions and it has been suggested that depletion of GSH may play a pathogenic role in some chronic viral diseases, such as AIDS. In this study GSH levels were measured in plasma and in peripheral blood mononuclear cells (PBMC) from patients with CHC who failed to respond to IFN therapy after at least 4 months of treatment. The effect of N-acetyl cysteine, a precursor of the thiol, was also evaluated on GSH levels and on the clinical and virological response to IFN therapy.

2. Patients and Methods

2.1 Patients

Fourteen patients (13 males and 1 female, mean age 51 years, range 27-71) diagnosed as suffering from CHC by histological and serological criteria, two of them with associated cirrhosis, were entered into the study. All of the patients had been under treatment with α -lymphoblastoid interferon (Wellferon) for a minimum period of 4 months (15 ± 1.6 MU per week, range 9-21 MU per week); all patients showed abnormal ALT values (above 30 IU/L) when entered into the study. Most patients with CHC responding to IFN, normalise transaminase levels within the first 3 months of therapy and those who persist with high ALT values after 4 months of treatment can be considered to be non-responders. Accordingly, all patients in the present study were considered to be non-responders to IFN. Patients in the present study continued essentially the same IFN regimen as they had followed previously but added oral N-acetyl cysteine (NAC), 600 mg every 8 hours daily. No patient increased the interferon dosage after the addition of oral NAC, although in 3 cases the amount of interferon was slightly reduced (15 ± 1.8 MU/week before NAC versus 11.5 ± 1.3 MU/week after NAC).

In addition 10 patients (8 males and 2 females, mean age 32 years, range 24-63) recently diagnosed as suffering from having chronic hepatitis C, who had never received antiviral treatment took the same amount of oral NAC, but without interferon, over a period of one month.

WO 94/14473

13

PCT/GB93/02600

Twenty-six healthy subjects (14 males and 12 females, mean age 43 years, ranging from 25 to 79) served as control group. All patients gave written informed consent and the study was approved by the Local Ethics Committee.

2.2 GSH determination in PBMC and plasma

Blood samples for simultaneous determinations of GSH in PBMC (L-GSH) and in poor-platelet plasma (P-GSH) were obtained from each patient. PBMC were isolated by centrifugation on Lymphoprep (Nycomed Pharma AS, Oslo, Norway) and washed five times. Isolated cells were killed with 20% perchloric acid (2% final concentration), and after centrifugation (1200g x 10 minutes at 4°C), and supernatants stored at -40°C, until use. Twenty percent perchloric acid was added to the poor platelet plasmas (2% final concentration), and after centrifugation, the supernatants were kept at -40°C until GSH determination.

Stored samples were thawed and GSH determined following the enzymatic method described by Brigellus et al., Biochem. Pharmacol., 32, 2529-2534 (1983) as modified by Ferrer et al., Biochem. J., 264, 531-534 (1990). GSH, in the presence of GSH-S-transferase, is conjugated with 1-chloro-2,4-dinitrobenzene (CDNB)(SIGMA), and the absorbance of the complex measured at 340 nm using a Perkin-Elmer Lambda 2 spectrophotometer. Absolute values of GSH were obtained using a molar extinction coefficient of 9.6×10^3 .

2.3 Extraction of RNA and RT-PCR

Reverse transcription polymerase chain reaction (RT-PCR) for HCV-RNA in serum and for either the positive or negative strands of HCV-RNA in PBMC was performed essentially as described by Ruiz et al., Hepatology, 16, 637-643 (1992) and Cheng et al., J. Hepatol., in press (1992). The procedures recommended by Kwoks and Higuchi, Nature, 339, 237-238 (1989), to reduce the risk of contaminations were strictly applied. All extractions and reactions were simultaneously carried out in positive and negative controls. An aliquot from the last washing of PBMC was also included, and PCR was always negative in these samples.

2.4 Statistical Analysis

All data are presented as means \pm standard error of mean (SEM). Comparisons for paired and impaired data were carried out using the Mann Whitney and Wilcoxon tests.

3. Figures

The results are described with reference to the accompanying drawings in which:

Figure 1 shows the effect of IFN (-4 to 0 months) and IFN plus NAC (0 to 6 months) on ALT levels for the 14 patients entered into the study;

Figure 2 shows the detection in PBMCs of positive and negative strands of HCV-RNA during treatment with IFN and with IFN plus NAC;

Figure 3 shows the detection of HCV-RNA in serum at a serum dilution of 1:10 both before and after addition of NAC to the treatment with IFN.

Figure 4 shows the mean ALT levels for the same patient population depicted in Figure 1 when followed up to eleven months after introduction of NAC to the IFN therapy.

4. Results

Mean serum ALT levels for the 14 patients entered into the study are shown in the following table which also shows L-GSH and P-GSH.

WO 94/14473

PCT/GB93/02600

- 15 -

TABLE

Month	Mean ALT (IU/L)	L-GSH (nMol/10 ⁶ cells)	P-GSH (lm)
-4	139 ± 24	-	-
0	124 ± 24	1.45 ± 0.27	0.77 ± 0.21
+1-2	87 ± 9	-	-
+3-4	53 ± 7	3.32 ± 0.18	2.40 ± 0.20
+5-6	37 ± 3	-	-

Values for L-GSH and P-GSH for the control group were as follows:

L-GSH 3.43 ± 0.89 nMol/10⁶ cells
P-GSH 18.1 ± 4.08 nM.

In patients with chronic hepatitis C who had never received antiviral treatment (n = 10), GSH levels in plasma (0.63 ± 0.07 lM) and in PBMC (1.02 ± 0.09 nMol/10⁶ cells) appeared severely depressed in comparison with healthy controls (18.1 ± 4.08 lM and 3.43 ± 0.89 nMol/10⁶ cells respectively, P < 0.01). The administration of NAC during 1 month significantly increased the levels of GSH in PBMC (2.22 ± 0.38 nMol/10⁶ cells, P < 0.05) but GSH in plasmas was not significantly modified (0.99 ± 0.22 lM, n.s). In addition, the levels of serum ALT (128 ± 32 IU/L versus 110 ± 29 IU/L after one month of therapy with NAC) were also not significantly modified.

In patients not responding to interferon, GSH levels in PBMC (1.45 ± 0.27 nMol/10⁶ cells) and in plasma (0.77 ± 0.21 lM) also appeared significantly depressed in comparison with control values (p < 0.01). In these patients, the administration of

WO 94/14473

PCT/GB93/02600

- 16 -

NAC together with interferon over a period of 3.4 months resulted in a significant elevation of GSH in mononuclear cells ($3.32 \pm 0.18 \text{ nMol}/10^6$ cells, $p < 0.05$) and in plasma ($2.40 \pm 0.20 \text{ lm}$, $p < 0.05$).

Figure 1 and the above Table show that in the patients entered into the study (non responders to interferon) ALT levels did not change significantly during 4 months of IFN therapy (139 ± 24 versus $124 \pm 17 \text{ IU/L}$, n.s). However, the addition of oral NAC resulted in a prompt and significant decrease of ALT; even after only one month of the combined treatment ALT values had significantly decreased ($87 \pm 9 \text{ IU/L}$, $p < 0.05$). Moreover, continuous administration of IFN and NAC over a period of 5-6 months produced a further decline in ALT values in all cases ($37 \pm 4 \text{ IU/L}$), reaching normal values in 41% of cases and near normal values (maximum of 56 IU/L in one case) in the remainder. The addition of NAC to the IFN regimen clearly improves the response to IFN in the case of patients previously classified as non-responders to IFN therapy.

The reduction in ALT levels by the combination of IFN and NAC was accompanied by a concomitant effect on the replication of the virus. In the case of 9 patients classified as non-responders to IFN, PBMC were tested for the presence of both the genomic strand of HCV (positive RNA strand) and the replicative intermediate of the virus (negative RNA strand), before and after addition of NAC to the therapy. As shown in Figure 2 when patients were being treated with IFN only, the genomic strand could be detected in 7 cases (77%), whilst the replicative intermediate was detected in 3 patients (33%). However, after 4-6 months of combined therapy with IFN and NAC, the positive strand was detected in only 2 cases (22%) and the negative HCV-RNA strand could not be detected in any of the cases.

Addition of NAC to the IFN regimen was also accompanied by decreased levels of HCV-RNA in serum. As shown in Figure 3, after NAC addition of NAC to the therapy an increased concentration of serum was needed for HCV detection; thus, before NAC addition HCV-RNA could be detected in 100% of cases using a serum dilution of 1:10, whilst after addition of NAC to the therapy at the same serum dilution, the virus was detected in only 70% of patients.

WO 94/14473

PCT/GB93/02600

- 17 -

CLAIMS:

1. A potentiated combination comprising a human interferon and a free radical scavenger or a precursor or inducer thereof.
2. A combination according to Claim 1, wherein the human interferon is human interferon- α .
3. A combination according to Claim 2, wherein the human interferon- α is recombinant.
4. A combination according to Claim 2, wherein the human interferon- α is natural.
5. A combination according to Claim 4, wherein the natural human interferon- α is human lymphoblastoid interferon.
6. A combination according to any of Claims 1 to 5, wherein the free radical scavenger or precursor or inducer thereof is glutathione or a precursor or inducer thereof.
7. A combination according to any of Claims 1 to 5, wherein the free radical scavenger or precursor or inducer thereof is N-acetyl cysteine.
8. A combination according to any of Claims 1 to 7, for use in the treatment of a condition susceptible to therapy with an interferon.
9. A combination according to Claim 8, wherein the condition is hepatitis B or hepatitis C infection.
10. The use of a human interferon for the manufacture of a medicament for use in the treatment of a patient suffering from a condition susceptible to therapy with a human interferon by a method wherein a free radical scavenger or a precursor or inducer thereof is also administered during the treatment with the human interferon.
11. The use of a free radical scavenger or a precursor or inducer thereof for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to therapy with a human interferon by a method involving

WO 94/14473

PCT/GB93/02600

- 18 -

treatment with a human interferon and the free radical scavenger or a precursor or inducer thereof interferon.

12. Use according to either of Claims 10 to 11, wherein the human interferon is human interferon- α .
13. Use according to Claim 12, wherein the human interferon- α is recombinant.
14. Use according to Claim 12, wherein the human interferon- α is natural.
15. Use according to Claim 14, wherein the natural human interferon- α is human lymphoblastoid interferon.
16. Use according to any of Claims 10 to 15, wherein the free radical scavenger or precursor or inducer thereof is glutathione or a precursor or inducer thereof.
17. Use according to any of Claims 10 to 15, wherein the free radical scavenger or precursor or inducer thereof is N-acetyl cysteine.
18. Use according to any of Claims 10 and 17 wherein, the condition is hepatitis B or hepatitis C infection.
19. The use of a human interferon for the manufacture of a medicament for use in the treatment of a patient suffering from a condition susceptible to therapy with a human interferon who has failed to respond to treatment with the human interferon, by a method wherein a free radical scavenger or a precursor or inducer thereof is also administered during the treatment with the human interferon.
20. The use of a free radical scavenger or a precursor or inducer thereof for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to therapy with a human interferon who has failed to respond to treatment with the human interferon, by a method involving treatment with a human interferon and the free radical scavenger or a precursor or inducer thereof.
21. Use according to either of Claims 19 and 20, wherein the patient has previously responded to treatment with the human interferon.

WO 94/14473

PCT/GB93/02600

- 19 -

22. Use according to anyone of Claims 19 to 21, wherein the human interferon is human interferon- α .
23. Use according to Claim 22, wherein the human interferon- α is recombinant.
24. Use according to Claim 22, wherein the human interferon- α is natural.
25. Use according to Claim 24, wherein the natural human interferon- α is human lymphoblastoid interferon.
26. Use according to any of Claims 19 to 25, wherein the free radical scavenger or precursor or inducer thereof is glutathione or a precursor or inducer thereof.
27. Use according to any of Claims 19 to 25, wherein the free radical scavenger or precursor or inducer thereof is N-acetyl cysteine.
28. Use according to any of Claims 19 to 27, wherein the condition is hepatitis B or hepatitis C infection.
29. A pharmaceutical formulation, which comprises a combination as described in any of Claims 1 to 7 and a pharmaceutically acceptable carrier.
30. A twin pack comprising in association the components required to be administered in order to generate a combination as described in any of Claims 1 to 7.
31. A method for the treatment of a patient suffering from a condition susceptible to therapy with a human interferon which comprises administering to the patient a therapeutically effective amounts of the human interferon and a free radical scavenger or a precursor or inducer thereof.
32. A method according to Claims 31 wherein the human interferon is human interferon- α .
33. A method according to Claim 32, wherein the human interferon- α is recombinant.
34. A method according to Claim 32, wherein the human interferon- α is natural.

WO 94/14473

PCT/GB93/02600


- 20 -

35. A method according to Claim 34, wherein the natural human interferon- α is human lymphoblastoid interferon.
36. A method according to any of Claims 31 to 35, wherein the free radical scavenger or precursor or inducer thereof is glutathione or a precursor or inducer thereof.
37. A method according to any of Claims 31 to 35, wherein the free radical scavenger or precursor or inducer thereof is N-acetyl cysteine.
38. A method according to any of Claims 31 to 37, wherein the condition is hepatitis B or hepatitis C infection.
39. A method for the treatment of a patient suffering from a condition susceptible to therapy with a human interferon who has failed to respond to treatment with the human interferon which comprises treatment of the patient with effective amounts of the human interferon and a free radical scavenger or precursor or inducer thereof.
40. A method according to Claim 39, wherein the patient has previously responded to treatment with the human interferon.
41. A method according to either of Claims 39 and 40 wherein the condition is hepatitis B or hepatitis C infection.

WO 94/14473

PCT/GB93/02600

1/4



SUBSTITUTE SHEET

WO 94/14473

PCT/GB93/02600

2 / 4




FIG. 2

WO 94/14473

PCT/GB93/02600

3/4





FIG. 3

WO 94/14473

PCT/GB93/02600

4 / 4



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

Intern.	Application No
	PCT/GB 93/02600

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K37/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 269 017 (CETUS CORPORATION) 1 June 1988 cited in the application see page 4, line 40 - page 6, line 3 ---	1-41
X	FR,A,2 290 222 (G.D. SEARLE & B CO., LIMITED) 4 June 1976 see page 1, line 10 - page 3, line 34 ---	1-41
X	US,A,4 762 705 (DAVID RUBIN) 9 August 1988 see column 2, line 40-55 see column 3, line 46 - column 4, line 5 --- -/--	1,6,10, 16,20, 26, 29-31, 36,39

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

25 March 1994

Date of mailing of the international search report

21. 04. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Rempp, G

INTERNATIONAL SEARCH REPORT

Intern: J Application No

PCT/GB 93/02600

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 100 150 (TERENCE CARTWRIGHT) 11 July 1978 see column 1, line 7 - column 3, line 18 ---	1-41
A	CANCER RESEARCH vol. 45, no. 8 , August 1985 pages 3444 - 3447 PIETRO GHEZZI ET AL. 'ROLE OF REACTIVE OXYGEN INTERMEDIATES IN THE INTERFERON-MEDIATED DEPRESSION OF HEPATIC DRUG METABOLISM AND PROTECTIVE EFFECT OF N-ACETYLCYSTEINE IN MICE.' see the whole document -----	1,7,10, 11,17, 19,20, 27,31, 37,39

INTERNATIONAL SEARCH REPORT

Internal application No.

PCT/GB93/02600

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark : Although claims 31 to 41 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: 1 Application No

PCT/GB 93/02600

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0269017	01-06-88	CA-A- 1321349 DE-A- 3780770 ES-T- 2042529 JP-A- 63190831 US-A- 4985241	17-08-93 03-09-92 16-12-93 08-08-88 15-01-91
FR-A-2290222	04-06-76	GB-A- 1526205 BE-A- 835355 CA-A- 1059029 DE-A- 2549768 JP-A- 51091320	27-09-78 01-03-76 24-07-79 20-05-76 10-08-76
US-A-4762705	09-08-88	NONE	
US-A-4100150	11-07-78	NONE	